



**Figure S9.** Schematic diagram shows the mechanism by which IL-17<sup>+</sup> MSCs attenuate immunosuppressive capacities, but possess increased anti-*C. albicans* activity. IL-17, produced by IL-17<sup>+</sup> MSCs, activates NFκB pathway in MSCs. NFκB can directly bind to TGF-β promoter region to downregulate TGF-β expression, resulting in abolishment of MSC-based immunomodulation. Meanwhile, IL-17<sup>+</sup> MSCs show increased anti-*C. albicans* effect.